6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-28), VYNE Therapeutics's 6-1 Month Momentum % is -35.91%.
The industry rank for VYNE Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
VYNE's 6-1 Month Momentum % is ranked worse than 78.3% of 1525
companies
in the Biotechnology industry
Industry Median: -5.52
vs VYNE: -35.91
Competitive Comparison of VYNE Therapeutics's 6-1 Month Momentum %
For the Biotechnology subindustry, VYNE Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VYNE Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
VYNE Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of VYNE Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
VYNE Therapeutics (VYNE Therapeutics) Business Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VYNE has been successfully added to your